Skip to main content
Premium Trial:

Request an Annual Quote

CytRx Licenses RNAi Technology from U Mass Medical School

NEW YORK, April 21 - CytRx has signed a license agreement with the University of Massachusetts Medical School for its proprietary portfolio of applications for RNAi-based gene silencing technology in obesity, type 2 diabetes, and cancer.


As part of the agreement, CytRx will issue UMMS approximately 1.6 million shares of its common stock, establishing the university as the company's second-largest shareholder.


CytRx said the suite of applications it is licensing from UMMS "may be considered the world's largest proprietary portfolio" of such technology. UMMS faculty member Craig Mello and Andrew Fire of the Carnegie Institution of Washington developed the approach, which uses RNA to selectively turn off the harmful genes of infectious viruses or malignant tumor cells, in 1997.


Louis Ignarro, chairman of CytRx's scientific advisory board, will head up the gene silencing research collaboration between CytRx and UMMS.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.